image
Healthcare - Biotechnology - NASDAQ - US
$ 18.85
2.56 %
$ 606 M
Market Cap
-6.66
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DNTH stock under the worst case scenario is HIDDEN Compared to the current market price of 18.9 USD, Dianthus Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DNTH stock under the base case scenario is HIDDEN Compared to the current market price of 18.9 USD, Dianthus Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DNTH stock under the best case scenario is HIDDEN Compared to the current market price of 18.9 USD, Dianthus Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DNTH

image
$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
6.24 M REVENUE
120.63%
-102 M OPERATING INCOME
-111.45%
-85 M NET INCOME
-95.08%
-78.2 M OPERATING CASH FLOW
-112.09%
-287 M INVESTING CASH FLOW
-1416.15%
256 M FINANCING CASH FLOW
91.37%
1.16 M REVENUE
-12.29%
-33.2 M OPERATING INCOME
-3.95%
-29.5 M NET INCOME
-3.77%
-27.6 M OPERATING CASH FLOW
-0.68%
14.8 M INVESTING CASH FLOW
164.02%
161 K FINANCING CASH FLOW
-99.59%
Balance Sheet Dianthus Therapeutics, Inc.
image
Current Assets 281 M
Cash & Short-Term Investments 275 M
Receivables 807 K
Other Current Assets 4.86 M
Non-Current Assets 93.1 M
Long-Term Investments 81.7 M
PP&E 1.75 M
Other Non-Current Assets 9.63 M
73.59 %21.85 %Total Assets$374.0m
Current Liabilities 18.5 M
Accounts Payable 4.58 M
Short-Term Debt 320 K
Other Current Liabilities 13.6 M
Non-Current Liabilities 3.08 M
Long-Term Debt 2.34 M
Other Non-Current Liabilities 737 K
21.27 %62.95 %10.88 %3.42 %Total Liabilities$21.5m
EFFICIENCY
Earnings Waterfall Dianthus Therapeutics, Inc.
image
Revenue 6.24 M
Cost Of Revenue 0
Gross Profit 6.24 M
Operating Expenses 108 M
Operating Income -102 M
Other Expenses -16.9 M
Net Income -85 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)6m06m(108m)(102m)17m(85m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-1633.74% OPERATING MARGIN
-1633.74%
-1362.77% NET MARGIN
-1362.77%
-24.11% ROE
-24.11%
-22.72% ROA
-22.72%
-28.62% ROIC
-28.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Dianthus Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -85 M
Depreciation & Amortization 412 K
Capital Expenditures -105 K
Stock-Based Compensation 12.9 M
Change in Working Capital -351 K
Others -14.7 M
Free Cash Flow -78.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Dianthus Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for DNTH of $52 , with forecasts ranging from a low of $52 to a high of $52 .
DNTH Lowest Price Target Wall Street Target
52 USD 175.86%
DNTH Average Price Target Wall Street Target
52 USD 175.86%
DNTH Highest Price Target Wall Street Target
52 USD 175.86%
Price
Max Price Target
Min Price Target
Average Price Target
5555505045454040353530302525202015151010Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Dianthus Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company's participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will host one-on-one meetings with investors. globenewswire.com - 1 month ago
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D. globenewswire.com - 1 month ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.54 per share a year ago. zacks.com - 1 month ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE'26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $331.5 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2025, and provided an update on recent business achievements. globenewswire.com - 1 month ago
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential  best-in-class, potent classical pathway inhibitor intended as a self-administered  autoinjector dosed once every two weeks NEW YORK and WALTHAM, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced completion of enrollment in the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis (gMG). globenewswire.com - 2 months ago
Dianthus Therapeutics to Participate in Two Upcoming Investor Events NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events. globenewswire.com - 2 months ago
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 3 months ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago. zacks.com - 3 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $357.0 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided an update on recent business achievements. globenewswire.com - 3 months ago
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion globenewswire.com - 4 months ago
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences: globenewswire.com - 4 months ago
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February: globenewswire.com - 5 months ago
8. Profile Summary

Dianthus Therapeutics, Inc. DNTH

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 606 M
Dividend Yield 0.00%
Description Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Contact 7 Times Square, New York City, NY, 10036 https://dianthustx.com
IPO Date June 21, 2018
Employees 78
Officers Mr. Edward G. Carr Chief Accounting Officer Mr. Adam M. Veness Esq. Senior Vice President, General Counsel & Secretary Mr. Scott Nogi M.B.A. Head of Business Operations Mr. Ryan Savitz Chief Financial Officer & Chief Business Officer Ms. Kristina Maximenko Chief People Officer Ms. Rashieda Gluck Head of Clinical Development Operations Mr. Judson Taylor Senior Vice President & Head of Technical Operations Mr. Marino Garcia M.B.A. President, Chief Executive Officer & Director Mr. Simrat Randhawa M.B.A., M.D. Chief Medical Officer Ms. Jennifer Davis Ruff Vice President and Head of Investor Relations & Corporate Affairs.